FDA Holds Zydus Cadila Responsible For ‘Repeat Violations’
Agency May Withhold Approval Of Abbreviated New Drug Applications
The FDA has published details of a warning letter summarizing significant violations of cGMP regulations to Zydus Cadila. The agency called the company’s prior response “insufficient.”
